DaVita Stock Forecast
NYSE: DVAHealth CareMisc Health and Biotechnology ServicesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
DVA analyst consensus
Consensus (8 analysts)
buy
Avg. price target
$219.86+24.37%
- Strong buy 0
- Buy 3
- Hold 4
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 8 Wall Street analysts covering DaVita (2026-10-07), 3 rate the stock a buy or strong buy, 4 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $219.86, with a high estimate of $270.00 and a low estimate of $165.00. The average target implies upside of 24.4% from the current price of $176.78.
The spread between the highest and lowest targets is 63.6%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for DVA.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 3 | 38% |
| Hold | 4 | 50% |
| Sell | 0 | 0% |
| Strong sell | 1 | 13% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $165.00 | -6.66% |
| Average target | $219.86 | +24.37% |
| High target | $270.00 | +52.73% |